drugset
drugset / Trial / NCT03746587

Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3

NCT03746587 ↗

Phase 2 Terminated 39 enrolled ZevraDenmark
RandomizedParallel-groupTriple-blindTreatment

Summary

Multicenter, doubleblinded, randomized placebo-controlled study of arimoclomol in patients with Gaucher Disease Type 1 or 3

Timeline

Start
2018-06-06
Primary completion
2020-04-01
Completion
2021-10-15

Outcome

Outcome not reported

Stopped: “COVID-19 pandemic made it impossible to assess the trial objective”

Drugs

EvaluationDrugModalityDoseRoute
Subject Arimoclomol Small molecule — Oral

Indications

Gaucher disease type I Gaucher disease type III